Individual responses to DUPIXENT can vary. Your experience with DUPIXENT may be different.
DUPIXENT has been studied in multiple clinical trials with various age groups—adults (ages 18+ years), teens (ages 12-17 years), children (ages 6-11 years), and young children (ages 6 months-5 years)—who suffer from uncontrolled moderate-to-severe eczema (atopic dermatitis).
In each clinical trial, results were measured at 16 weeks, with each age group taking DUPIXENT achieving visible skin improvement in that time compared with patients who were not administered DUPIXENT.
View Results in